Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 61 (pp. 832-860)    |    2018       

»

Glucocorticoid - induced osteoporosis: current state of the problem

Salukhov V.V., Kovalevskaya E.A.

S.M. Kirov Military Medical Academy, Saint Petersburg, Russia

Brief summary

The use of long-term courses of therapeutic doses of glucocorticoids, despite the introduction of new drugs is widely distributed. Along with this, the numerous side effects of steroid hormones, including the development of glucocorticoid-induced osteoporosis, are not always in the attention of physicians. Given the high prevalence of disorders of calcium-phosphorus metabolism in patients receiving glucocorticosteroids, in this article we will look at the pathogenetic aspects of bone metabolism dysfunction caused by the use of steroid drugs. In this review, we will analyze and summarize the recommendations of various European and American communities on the diagnosis, examination and treatment of osteoporosis that occurs while taking glucocorticoids.


Key words

osteoporosis, densitometry, vitamin D, glucocorticoids, glucocorticoid-induced osteoporosis

Reference list

1. Overman R.A. Prevalence of oral glucocorticoid usage in the United States: a general population perspective / R.A. Overman, J.Y. Yeh, C.L. Deal // Arthritis Care Res. (Hoboken) - 2013. - N 65. - R. 294-8.


2. Fractures after rheumatoid arthritis. A population-based study / J.R. Hooyman, L.J. [et al.] // Arthr. Rheum. - 1984. - N 12. - R. 1353-1361.


3. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis / J.N. Hoes[et al.] // Ann. Rheum. Dis. 2009. Vol. 68. P. 1833-8.


4. Cooper C. Rheumatoid arthritis, corticosteroid therapy and hip fracture / C. Cooper, C. Coupland, M. Mitchell // Ann. Rheum. Dis. - 1995. - Vol 54. - P. 49-52.


5. Fracture risk with intermittent high- dose oral glucocorticoid therapy / De Vries[et al.] // Arthritis Rheum. - 2007. - Vol. 56. - P. 208-14.


6. American College of Rheumatology. Task force on Osteoporosis Guidelines. Recommendations for the prevenion and treatment of glucocorticoid-induced osteoporosis / S. Braegger, [et al.] // Arthr. Rheum. - 1996. - Vol 39. - P 1791-1801.


7. Glucocorticoid-induced osteoporosis. Royal College of Physicians of London, 2002, // [ Elektronnii resyrs]. URL: www.rcplondon.ac.uk. (data obrasheniya: 10.02.2019).


8. Weinstein R.S. Glucocorticoid-induced bone disease // N. Engl J Med. - 2011. - Vol. 365. - P. 62-70.


9. Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis // Endocrinol. Metab. Clin. North. Am. - 2012. - Vol. 41. - P. 595-611.


10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial / S.T. Harris [et al.] // JAMA. - 1999. - Vol. 282. - P. 1344-1352.


11. Effects of risedronate on the risk of hip fracture in elderly women / M.R. McClung[et al.] // N. Engl. J. Med. - 2001. - Vol. 344. - P. 333-340.


12. Glukokortikoid-indycirovannii osteoporoz / I.S. Didikina [i dr.] // Naychno-prakticheskaya revmatologiya. - 2005. - ? 1. - S 69-75.


13. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses / T.P. van Staa, [et al.] // Rheumatology. - 2000. - Vol. 39, 12. - P. 1383-9.


14. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease / A. Jones [et al.] // The Cochrane Library. Issue I. - 2004. [ Elektronnii resyrs]. URL: https://www.cochrane.org/CD003537/AIRWAYS (data obrasheniya: 10.02.2019).


15. Long-term use of inhaled corticosteroids in COPD and the risk of fracture / A.V. Gonzalez, [et al.] // Chest. - 2018. - Vol. 153. - P. 321-8.


16. Inhaled corticosteroids and hip fracture / R.B. Hubbard [et al.] // Am. J. Resp. Crit. Care Med. - 2002.- Vol. 166. - P. 1563-66.


17. Health Care Guideline: diagnosis and treatment of osteoporosis / S. Allen [et al.] // Institute for Clinical System Improvement. - 2004. [Elektronnii resyrs]. URL: www.icsi.org (data obrasheniya: 10.02.2019).


18. Glukokortikoidindycirovannii osteoporoz y nevrologicheskih bolnih: meropriyatiya po profilaktike i lecheniu / K.V. Antonova [i dr.] // Nervno-mishechnie bolezni. - 2018. - Tom 7. - S 10-20.


19. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study / S.R. Majumdar [et al.] // J. Rheumatol. - 2013. - Vol. 40, 10. - P. 1736-1741.


20. Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database / S. Trijau [et al.] // RMD - 2016. - Open 2, e000249.


21. Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses / M.A. Amiche [et al.] // J. Bone Miner. Res. - 2017. - Vol. 33. - P. 419-429.


22. Comparison of trabecular bone architecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis / L. Dalle Carbonare, [et al.] // J. Bone Miner. Res. - 2001. - Vol.16. - P. 97-103.


23. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts / K. Ohnaka [et al.] // Biochem. Biophys. Res. Commun. - 2005. - Vol. 329. - P. 177-181.


24. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of SOST/sclerostin / A.Y. Sato [et al.] // J. Bone Miner. Res. - 2016. - Vol. 31. - P. 1791-1802.


25. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength / W. Yao [et al.] // Osteoporos. Int. - 2016. - Vol. 27,1. - P. 283-294.


26. Compston J. Glucocorticoid-induced osteoporosis: an update // Endocrine. - 2018. - Vol. 61. - P.7-16.


27. Panday K. Medication-induced osteoporosis: screening and treatment strategies / K. Panday, A. Gona, M.B. Humphrey // Ther. Adv. Musculoskelet. Dis.- 2014. - Vol. 6. - P. 185-202.


28. Glucocorticoid- induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines / G. Mazziotti [et al.] // Endocrine. - 2016. - Vol. 54,3. - P. 603-611.


29. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases / A.Y. Sato [et al.] // Endocrinology. - 2017. - Vol. 158,3. - P. 664-677.


30. Baranova I.A. Glukokortikoidindycirovannii osteoporoz: patogenez, profilaktika, lechenie // Sovremennaya revmatologiya. - 2008. - ? 1 - C. 31-39.


31. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis / L. Buckley [et al.] // Arthritis Care & Research. - 2017. - Vol. 69. - P. 1095-1110.


32. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study / R.F. Laan [et al.] // Ann. Intern. Med. - 1993. - Vol. 119. - P. 963-8.


33. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population- based cohort study / S.R. Majumdar [et al.] // Osteoporos Int. - 2013. - Vol. 24. - P. 2493-8.


34. Klinicheskie rekomendacii po profilaktike i vedeniu bolnih s osteoporozom. Rossiiskaya associaciya po osteoporozy. / L.I. Alekseeva [i dr.]. Yaroslavl: IPK «Litera», 2016. - 24 s.


35. Lesnyak O.M. Novaya paradigma v diagnostike i lechenii osteoporoza: prognozirovanie 10-letnego absolutnogo riska pereloma (kalkylyator FRAX) // Osteoporoz i Osteopatii. - 2012.- ?1. - S 23-28.


36. Glucocorticoid-induced osteoporosis: pathophysiology and therapy / E. Canalis [et al.] // Osteoporosis International. - 2007. - Vol. 18. - P. 1319-1328.


37. For the National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis / J. Compston [et al.] // Archives of Osteoporosis. - 2017. - Vol. 12. - P. 43.


38. Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid / T. Sugiyama [et al.] // Gender Medicine. - 2010. - Vol. 7. - P. 218-229.


39. For the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis / S. Lekamwasam [et al.] // Osteoporosis International. - 2012. - Vol. 23. - P. 2257-2276.


40. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis / L. Buckley [et al.] // Arthritis Rheumatol. - 2017. - Vol. 69. - P. 1521- 37.


41. Nacionalnoe rykovodstvo Endokrinologiya pod red. I.I. Dedova, G.A. Melnichenko M.: GEOTAR-Media, 2016. - 1112 s.


42. European guidance for the diagnosis and management of osteoporosis in postmenopausal women / J. Kanis [et al.] // Osteoporos Int. - 2013. - Vol. 24,1. - P. 23-57.


43. The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper / A. Quentin [et al.] // B.J.H. - 2019. - Vol. 1. - P. 1-8.


44. 1 National Osteoporosis Guideline Group: clinical guideline for the prevention and treatment of osteoporosis. [Elektronnii resyrs]. URL: https://www.sheffield. ac.uk/NOGG/ (2017). (data obrasheniya: 10.02.2019).


45. Exercise for preventing and treating osteoporosis in postmenopausal women / T.E. Howe [et al.] // Cochrane Database Systematic Review. - 2011. CD000333.


46. Calcium and vitamin D for corticosteroid-induced osteoporosis / J. Homik [et al.] // Cochrane Database Systematic Review. - 2000. CD000952.


47. Calcium and vita- min D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double- blind, placebo-controlled trial / L.M. Buckley [et al.] // Ann. Intern. Med. - 1996. - Vol. 125. - P. 961-8.


48. Vitamin D and calcium in the prevention gluicorticoid-induced osteoporosis: A3-year follow-up / J.D. Adachi [et al.] // J. Rheumatol. - 1996. - Vol. 23. - P.995-1000.


49. Salyhov V.V. Kostnie i vnekostnie effekti vitamina D a takje vozmojnosti medikamentoznoi korrekcii ego deficita / V.V. Salyhov, E.A. Kovalevskaya, V.V. Kyrbanova // Medicinskii sovet. - 2018. - ? 4 - C. 90-98.


50. Ringe J.D. Kalcii, vitamin D i ego metaboliti v lechenii osteoporoza, svyazannogo s dlitelnim priemom glukokortikoidov // RMJ. Osteoporoz i osteopatii. - 2002. - ? 1. - S 1022.


51. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients / S. Yamada [et al.] // Yakugaku Zasshi. - 2007. - Vol. 127. - P. 1491-6.


52. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial / M. Hakala [et al.] // Scand. J. Rheumatol. - 2012. - Vol. 41. - P. 260-6.


53. Compston J. Glucocorticoid-induced osteoporosis: an update // Endocrine. - 2018. - Vol. 61. - P.7-16. [Elektronnii resyrs]. URL:https://doi.org/10.1007/s12020-018-1588-2 (data obrasheniya: 10.02.2019).


54. Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: a systematic review / K.S. Khow [et al.] // J. Nutr. Health Aging. - 2017. - Vol. 21. - P. 83-91.


55. For the Joint IOF-ECTS GIO Guidelines Working Group. (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis / S. Lekamwasam [et al.] // Osteoporosis International. - 2012. - Vol. 23. - P. 2257-2276.


56. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial / P.D. Miller [et al.] // JAMA. - 2016. - Vol. 316. - P. 722-33.


57. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial / C.C. Glüer [et al.] // J. Bone Miner. Res. - 2013. - Vol. 28. - Vol. 1355-68.


58. Effect of denosumab compared with risedronate on percentage change in lumbar spine BMD at 12 months in subgroups of glucocorticoid-treated individuals / K. Saag [et al.] // American Society of Bone and Mineral Research Annual Meeting Abstracts. - 2017. FR0301 S109. [Elektronnii resyrs]. URL: https://acrabstracts.org/abstract/subgroup-analysis-of-the-effect-of-denosumab-compared-with-risedronate-on-percentage-change-in-lumbar-spine-bone-mineral-density-at-24-months-in-glucocorticoid-treated-individuals. (data obrasheniya: 10.02.2019).


59. Raloxifene for prevention of glucocorticoid- induced bone loss: a 12-month randomised double-blinded placebo-controlled trial / C.C. Mok [et al.] // Ann. Rheum. Dis. - 2011. - Vol. 70. - P. 778-84.


60. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women / E. Barrett-Connor [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - P. 125-37.


61. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis / A. Cranney [et al.] // Cochrane Database Syst. Rev. - 2000. - Vol. 2: CD001983.


62. RLS. Elektronnii resyrs]. URL: https://www.rlsnet.ru/tn_index_id_2097.htm#protivopokazaniya. (data obrasheniya: 10.02.2019).


63. Green S.B. Effects of maternal bisphosphonate use on fetal and neonatal outcomes / S.B. Green, A.L. Pappas // Am. J. Health Syst. Pharm. - 2014. - Vol. 71. - P. 2029-36.


64. Effect of risedronate on bone in renal transplant recipients / M. Coco [et al.] // J. Am. Soc. Nephrol. - 2012. - Vol. 23. - P. 1426-37.


65. Comment on 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis / M. Maricic [et al.] // Arthritis Care Res. - 2017. Elektronnii resyrs]. URL: https://doi.org/10.1002/acr.23424/ (data obrasheniya: 10.02.2019).


66. Buckley L. Glucocorticoid-Induced Osteoporosi / L. Buckley, B. Mary, M.D. Humphrey // The new England journal of medicine. - 2018. - Vol. 5. - P 2574-2556.


67. Phillip C. Witcher. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition / C. Witcher Phillip, G. Gabriela Loots, G. Robling Alexander // JCI Insight. - 2018. - Vol. 3, 11. :e98673. [Elektronnii resyrs]. URL:https://doi.org/10.1172/jci.insight.98673. (data obrasheniya: 12.02.2019).